Luigi Casella

Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson’s disease

Stanley Fahn, Jason Langley, Guillermo Horga, 2018, npj Parkinson's Disease.

Defi ning the organizational structure of dopamine and muscarninic acetylcholine receptors

N. Nalivaeva, F. Zucca, C. Bellei, 2015 .

DOPA pheomelanin is increased in nigral neuromelanin of Parkinson's disease and it exacerbates alpha-synuclein neurotoxicity

K. Wakamatsu, S. Ito, K. Yang, 2022, medRxiv.